Immune checkpoint inhibitors led to major advances in melanoma therapy, and pembrolizumab (anti-PD-1 monoclonal antibody) is now a new standard of treatment for advanced melanoma. The aim of this work was to discuss, on the basis of planned or ongoing clinical trials, future perspectives to improve the efficacy of pembrolizumab, such as combination regimens with other immunotherapies or targeted therapies.
|Translated title of the contribution||Combination strategies in melanoma therapy|
|Number of pages||5|
|Journal||Recenti Progressi in Medicina|
|Publication status||Published - Dec 1 2017|
ASJC Scopus subject areas